Publications by authors named "Joseph Boni"

Claim this Profile
Q
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy.
Yuezhe Li, A Katharina Wilkins, Jimena Davis, Timothy Knab, Marie Toukam, Joseph P Boni

NPJ Syst Biol Appl· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary.
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Joseph Boni

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine.
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Joseph Boni

EJHaem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Marie Toukam, Joseph P Boni, Mehdi Hamadani, Paolo F Caimi, Hans G Cruz

Cancer Chemother Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Marie Toukam, Jens Wuerthner, Karin Havenith, Mehdi Hamadani, Paolo F Caimi, Joseph P Boni

Cancer Chemother Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
Brian Hess, William Townsend, Weiyun Ai, Anastasios Stathis, Melhem Solh, Joseph Boni

AAPS J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Mehdi Hamadani, Graham P Collins, Paolo F Caimi, Felipe Samaniego, Alexander Spira, Joseph Boni

Lancet Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F Caimi, Erin Reid, Joseph Boni

Blood· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Aaron D Goldberg, Ehab Atallah, David Rizzieri, Roland B Walter, Ki-Young Chung, Joseph Boni

Leuk Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Brad S Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Joseph Boni

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
May Garrett, Ana Ruiz-Garcia, Kourosh Parivar, Brian Hee, Joseph Boni

J Pharmacokinet Pharmacodyn· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
Jennifer E Hibma, Hagop M Kantarjian, Daniel J DeAngelo, Joseph P Boni

Br J Clin Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
Wojciech Jurczak, Sundra Ramanathan, Pratyush Giri, Alessandra Romano, Heidi Mocikova, Joseph Boni

Leuk Lymphoma· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Randeep Sangha, Andrew Davies, Nam H Dang, Michinori Ogura, David A MacDonald, Joseph Boni

J Drug Assess· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
Daniel J DeAngelo, Wendy Stock, Anthony S Stein, Andrei Shustov, Michaela Liedtke, Joseph Boni

Blood Adv· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Joseph Boni

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.
Kenneth T Luu, Joseph Boni

Cancer Chemother Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Alison M Betts, Nahor Haddish-Berhane, John Tolsma, Paul Jasper, Lindsay E King, Joseph Boni

AAPS J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Richat Abbas, Joseph Boni, Daryl Sonnichsen

Drug Metab Pers Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Romano Danesi, Joseph P Boni, Alain Ravaud

Cancer Treat Rev· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Puja Sapra, Alison Betts, Joseph Boni

Expert Rev Clin Pharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Luis Fayad, Fritz Offner, Mitchell R Smith, Gregor Verhoef, Peter Johnson, Joseph Boni

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
Alan H Bryce, Ravi Rao, Jann Sarkaria, Joel M Reid, Yingwei Qi, Joseph Boni

Invest New Drugs· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.
Joseph P Boni, Cathie Leister, Bruce Hug, Jaime Burns, Daryl Sonnichsen

Cancer Chemother Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Birgit Geoerger, Mark W Kieran, Stephan Grupp, Danuta Perek, Jill Clancy, Joseph P Boni

Eur J Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis